Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemopoietic stem cell transplants for multiple myeloma

S Jagannath1, D H Vesole, G Tricot

  • 1Division of Hematology-Oncology, Arkansas Cancer Research Center, U of Arkansas for Medical Sciences, Little Rock.

Oncology (Williston Park, N.Y.)
|November 1, 1994
PubMed
Summary

High-dose therapy with autologous transplants offers significant remission rates and survival benefits for multiple myeloma patients. This approach has reduced procedure-related mortality to under 5%.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same author

Drug response prediction in high-risk multiple myeloma.

Gene·2017
Same author

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017
Same author

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.

Leukemia·2017
Same author

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2017

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • High-dose therapy is increasingly evaluated for multiple myeloma.
  • Autologous transplantation, supported by peripheral blood stem cells, has become a primary approach.

Purpose of the Study:

  • To review the efficacy and safety of high-dose therapy with autologous transplants in multiple myeloma.
  • To compare outcomes with allogeneic transplantation.

Main Methods:

  • Evaluation of data on autologous transplantation using peripheral blood stem cells.
  • Analysis of complete response rates, event-free survival, and overall survival.
  • Review of procedure-related mortality for both autologous and allogeneic transplants.

Main Results:

Related Experiment Videos

  • Autologous transplants achieve complete remissions in up to 50% of patients within 12 months of initial therapy.
  • Median event-free survival is approximately 2.5 years, and overall survival is 4-5 years with autologous transplants.
  • Allogeneic transplantation shows lower response rates and significantly higher mortality (approx. 40%) but can lead to long-term survival in 35-40% of patients.

Conclusions:

  • High-dose therapy with autologous transplantation is a safe and effective treatment for multiple myeloma, with reduced mortality and improved survival.
  • Allogeneic transplantation offers an alternative but carries higher risks.
  • Further direct comparisons between standard therapy and autologous transplants are warranted.